A Phase III, Open-Label, Parallel, Randomized, Multicenter Study Evaluating the Safety of 25 And 50 mg Proellex (CDB-4124) in the Treatment of Premenopausal Women With Symptomatic Uterine Fibroids.

Trial Profile

A Phase III, Open-Label, Parallel, Randomized, Multicenter Study Evaluating the Safety of 25 And 50 mg Proellex (CDB-4124) in the Treatment of Premenopausal Women With Symptomatic Uterine Fibroids.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2014

At a glance

  • Drugs Telapristone (Primary)
  • Indications Uterine leiomyoma
  • Focus Adverse reactions
  • Sponsors Repros Therapeutics
  • Most Recent Events

    • 17 Feb 2010 Actual end date (Aug 2009) and actual number of patients (175) added as reported by ClinicalTrials.gov.
    • 14 Aug 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 03 Aug 2009 Status changed from recruiting to suspended, according to a Repros Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top